StockData

Mosaic ImmunoEngineering Inc. (CPMV) stock

CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.33+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.41MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$2.41M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$687.35K
EPS, diluted
-$0.08
Book value per share
-$1.08
Diluted shares
7M

Trading

Previous close
$0.33
Open
$0.33
Day's range
$0.33 – $0.33
Volume
0

Market cap history

Month-end market cap since 2013, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodCPMVS&P 500DifferenceCPMV per yearS&P 500 per year
1 month+291.8%+0.6%+291.1 pts
3 months-47.9%+3.4%−51.2 pts
Year to date+7.1%+13.3%−6.2 pts
1 year-68.3%+16.6%−84.9 pts
3 years-41.6%+86.4%−128.0 pts-16.4%+23.1%
5 years-72.2%+81.9%−154.1 pts-22.6%+12.7%
10 years-90.5%+318.9%−409.3 pts-21.0%+15.4%

Fifteen years at a glance

Fiscal years 2010 to 2025 and trailing twelve months, USD

Operating income

-$604.01K

Net income

-$687.35K

EPS, diluted

-$0.08

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Mosaic ImmunoEngineering filed with the SEC as exhibits to Form 8-K or 6-K

About Mosaic ImmunoEngineering

Biological Products, (No Diagnostic Substances)

Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and commercializing immunotherapies for the treatment of cancer. The company works to identify, acquire, or license new product candidates and platforms to construct a product pipeline centered around cancer immunotherapy treatments. It has previously engaged in advisory and related services for external study projects. The company does not currently maintain an active development pipeline and seeks to serve medical patients through potential future therapeutic solutions.

Company profile, executives and history

Mosaic ImmunoEngineering stock: common questions

What is Mosaic ImmunoEngineering's stock price?

CPMV closed at $0.33 on Oct 19, 2026, up 0.00% on the day.

What is Mosaic ImmunoEngineering's market cap?

Mosaic ImmunoEngineering was worth $2.41M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is CPMV's P/E ratio?

Mosaic ImmunoEngineering lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.08), so it has no meaningful P/E ratio.

Does Mosaic ImmunoEngineering pay a dividend?

No. Mosaic ImmunoEngineering has not paid a cash dividend over the last twelve months.

How has CPMV stock performed over the past year?

Including dividends, CPMV returned -68.3% over the past year, against +16.6% for the S&P 500.

Who are Mosaic ImmunoEngineering's competitors?

Companies most similar to Mosaic ImmunoEngineering by business, industry and size include CERO, TIL, CLDI, INAB, LIMN.

See a number that looks wrong?